Cary Street Partners Investment Advisory’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$131K Buy
2,731
+1,454
+114% +$62.5K 0.03% 455
2026
Q1
$46.9K Sell
1,277
-241
-16% -$11.4K 0.01% 551
2025
Q4
$77.2K Buy
1,518
+338
+29% +$17.3K 0.02% 456
2025
Q3
$65.5K Sell
1,180
-1,266
-52% -$74.1K 0.03% 411
2025
Q2
$169K Buy
2,446
+320
+15% +$21.8K 0.08% 270
2025
Q1
$148K Buy
2,126
+1,091
+105% +$90.1K 0.09% 256
2024
Q4
$89K Sell
1,035
-4,813
-82% -$520K 0.06% 268
2024
Q3
$696K Buy
5,848
+915
+19% +$122K 0.03% 428
2024
Q2
$704K Buy
4,933
+289
+6% +$38.3K 0.03% 393
2024
Q1
$596K Buy
4,644
+663
+17% +$78.9K 0.03% 422
2023
Q4
$412K Buy
3,981
+204
+5% +$20.2K 0.02% 456
2023
Q3
$343K Buy
3,777
+3
+0.1% +$264 0.02% 454
2023
Q2
$305K Sell
3,774
-32
-0.8% -$2.61K 0.02% 436
2023
Q1
$303K Sell
3,806
-48
-1% -$3.4K 0.02% 406
2022
Q4
$261K Buy
+3,854
New +$226K 0.02% 424
2022
Q3
Sell
-3,394
Closed -$189K 545
2022
Q2
$189K Buy
+3,394
New +$188K 0.02% 427

Other funds holding NVO

Cary Street Partners Investment Advisory's NVO Position: Q2 2026 in Review

Cary Street Partners Investment Advisory increased its Novo Nordisk (NVO) stake by 114% in Q2 2026, buying an estimated $62.5K and bringing the position to 2,731 shares worth $131K. The position accounts for 0.03% of the portfolio, ranked #455.

Cary Street Partners Investment Advisory first reported a position in NVO in Q2 2022 and has held it in 16 quarters since. The position peaked at $704K in Q2 2024. 1,113 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Cary Street Partners Investment Advisory held 2,731 shares of Novo Nordisk worth $131K as of Q2 2026.
  • Cary Street Partners Investment Advisory bought 1,454 Novo Nordisk shares in Q2 2026, an estimated $62.5K.
  • Novo Nordisk made up 0.03% of Cary Street Partners Investment Advisory's portfolio in Q2 2026, its #455 holding.
  • Cary Street Partners Investment Advisory first reported a position in Novo Nordisk in Q2 2022 and has held it in 16 quarters since.
  • Cary Street Partners Investment Advisory's Novo Nordisk position peaked at $704K in Q2 2024.
  • 1,113 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Cary Street Partners Investment Advisory's 13F filing for Q2 2026, filed 17 Jul 2026.